Summit Therapeutics 2024财年第四季度调整后每股亏损$(0.07),超过预期的$(0.08)

财报速递
24 Feb
Summit Therapeutics(纳斯达克股票代码:SMMT)报告季度每股亏损$(0.07),超过分析师一致预期的$(0.08),增幅12.5%。

以上内容来自Benzinga Earnings专栏,原文如下:

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10